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Abstract
Background: Creutzfeldt-Jakob disease (CJD) is a prion disease characterized by misfolded proteins that lead to neurodegeneration and 
inevitable death. Classic sporadic CJD presents primarily with cognitive symptoms and ataxia without visual impairment at the onset 
of the illness. Seizure activity is a rare presentation of patients with sporadic CJD. Case: We present a rare case of rapidly progressive 
encephalopathy in a 57-year-old female who presented to the emergency department with bizarre behavior and vision deterioration. 
Imaging was unrevealing, and infectious and organic causes were ruled out. Electroencephalogram showed evidence of encephalopathy 
and non-convulsive status epilepticus. Magnetic resonance imaging conducted later displayed high signal intensity in centrum ovale. The 
patient’s history, results from diagnostic analyses, and clinical presentation suggested the diagnosis of CJD (sporadic type). Conclusion: 
Due to the low incidence and varying clinical presentations, it is difficult to include CJD in a differential diagnosis without specific analytic 
measures. However, for the benefit of the patient and healthcare resources, CJD needs to be quickly considered when rapid neurological 
decline or non-convulsive status epilepticus is not suggestive of another entity.
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Introduction
Creutzfeldt-Jakob disease (CJD), the most iconic of the human 
prion pathologies, is characterized by misfolded proteins that 
lead to neurodegeneration and inevitable death. CJD displays 
an exceedingly fast rate of deterioration, with a median time 
from onset of symptoms to death of 12 months. The time 
from onset of symptoms to diagnosis varies, with a median of 
approximately 6 months.1 With an estimated incidence of one 
to two per million people annually, CJD is a rare but important 
consideration in the differential diagnosis of rapid neurodege-
neration.2,3
Four major types of CJD exist: iatrogenic, variant, familial, and 
sporadic CJD.2 Sporadic CJD (sCJD) is responsible for 85% of 
CJD.3,4 Compared to other CJDs, sCJD has been shown to occur 
at a later age and affect women more frequently than men.5 
Symptoms of sCJD include personality changes, sleep distur-
bances, cognitive function decline, behavioral abnormalities, 
visual abnormalities, hallucinations, cerebellar dysfunction, 
memory decline, myoclonus, progressive dementia, a positive 
startle reflex, and pyramidal dysfunction.5
Several subtypes of sCJD have been studied. Classic sCJD has 
been described primarily with cognitive symptoms and ataxia 
without visual impairment at the onset of the illness. Classic 
sCJD notoriously has a short interval between symptom onset 
and diagnostic evaluation.3 Seizure activity is a rare presenta-
tion in sCJD, and a review of the literature up to 2010 found 
that 12 patients have been reported to present with CJD and 
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Key Points:
• Creutzfeldt-Jakob disease (CJD), particularly the sporadic subtype, is 
a devastating disease with a rapid neurological degeneration pattern.
• In the case of unknown causes of neurodegenerative decline, CJD 
should be included in the differential, and the laboratory testing should 
be initiated early in management.
• A short window of time exists between symptom onset and death, 
and diagnosis early in this window allows the patient to carry out his/
her final wishes and the family time for closure.
nonconvulsive status epilepticus (NCSE).6 In this report, we 
present a rare case of rapidly progressive encephalopathy in a 
57-year-old female, who presented with cognitive decline and 
NCSE, which lead to the diagnosis of sCJD. All appropriate con-
sents, including the use of this case for educational or research 
purposes, were obtained from the patient prior to admission.
The Case
A 57-year-old Hispanic female presented to our facility for an 
involuntary psychiatric evaluation for depression. The patient 
appeared disoriented and confused, with limited response to 
verbal/non-verbal cues and a flattened affect. According to the 
patient’s spouse, the symptoms began three months prior to 
presentation with changes in vision and a decrease in responsi-
veness. Symptoms progressed, and the patient eventually had 
difficulty maintaining her employment. The spouse described 
her as having an unfocused gaze that fluctuated, difficulty with 
coordination, personality changes, and a decline in activities 
of daily living. She spent most of her day in silence. The day 
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after her admission, neurology specialist was consulted for the 
patient’s altered mental status, and a full physical exam was 
limited by the patient’s declining health. The initial computed 
tomography (CT) scan and magnetic resonance imaging (MRI) 
scan of her brain were unremarkable. An electroencephalogram 
(EEG) was also ordered to rule out an epileptic cause for the 
patient’s episodes of unresponsiveness. Before the tests were 
administered, the patient was reported to have uncontrolled 
arm movements that prompted a transfer to the Emergency 
Room at Palmetto General Hospital. In the emergency room, 
tests for rapid plasma reagin (RPR), B12, folate, thyroid stimu-
lating hormone (TSH), and ammonia levels were ordered. At 
this point, the patient was still mildly alert and able to follow 
simple commands. She did, however, exhibit bizarre behavior, 
including anger, anxiety and irritability. 
The video EEG was very concerning, as it showed symmetric/
reactive background slowing activity at 5 Hz with intermittent 
triphasic morphology consistent with moderate-to-severe en-
cephalopathy, as well as NCSE. Subsequent EEGs were consis-
tent with these findings, and treatment was attempted with 
phenytoin (Dilantin). After anticonvulsant therapy failed to 
reverse or slow the rate of her neurodegeneration, a lumbar 
puncture was ordered for the analysis of 14-3-3 and tau pro-
tein for a suspected rapidly progressing encephalopathy. After 
a week of deteriorating and inconclusive laboratory analysis, 
the patient’s history of gastric band surgery prompted further 
laboratory tests. Her thiamine level was below normal limits, 
which prompted concern for the possibility of Wernicke or Kor-
sakoff encephalopathy. Thiamine levels were replaced without 
an improvement in neurological function. Repeat EEGs conti-
nued to show signs of encephalopathy with generalized sharp 
wave discharges that appeared to be epileptiform in nature 
(Figure 1). While awaiting the results of 14-3-3 and tau protein 
immunoassay, other laboratory tests returned negative results, 
including the tests for human immunodeficiency virus (HIV) 
and herpes simplex virus (HSV). At this point, the differential 
diagnosis was almost completely narrowed down to CJD. Au-
toimmune encephalitis, mitochondrial disease, heavy metal to-
xicity, paraneoplastic panel, derangements in amino acids, and 
organic acids and carnitine abnormalities were all ruled out.
Several days later, a repeat MRI revealed a single area of hyper-
intensity involving the right centrum semiovale consistent with 
a non-specific white matter lesion (Figure 2). The cerebrospinal 
fluid (CSF) was positive for 14-3-3, and tau protein immunoas-
say revealed a tau protein level of 6,350 mg/dL. The patient’s 
clinical presentation, along with supporting results from MRI, 
EEG, 14-3-3 and tau protein immunoassay, all supported the 
diagnosis of CJD. While the definitive diagnosis was only achie-
ved post-mortem, the findings were discussed with an expert 
in prion disease at the University of Chicago, who agreed with 
the likely diagnosis of CJD. The family, once informed of the 
findings, gave consent to genetic and post-mortem analysis. 
The patient later received hospice care, and the National Prion 
Surveillance Center had been informed of impending autopsy 
for genetic analysis.
Discussion
The patient presented with severe neurological dysfunctions 
as demonstrated by her disorientation, confusion, flat affect, 
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and limited responsiveness. However, retrospective questio-
ning revealed that while these symptoms brought her to the 
hospital, other symptoms had been present for months. This 
considerable length of time is significant in that it represents a 
large portion of the total duration from disease onset to even-
tual death. Furthermore, CJD was only considered after the EEG 
demonstrated refractory NCSE and reversible causes of CJD had 
been ruled out, adding to the delay in probable diagnosis.
NCSE is an atypical finding in cases of sCJD, with only 12 cases 
being reported prior to this.6 Patients displaying this symp-
tomatology were treated as having refractory NCSE and were 
non-responsive to multiple doses of antiepileptic drugs. Our 
patient was also unresponsive to several doses of phenytoin 
(Dilantin), which prompted the workup for sCJD.
The early stages of sCJD are largely nonspecific, making it di-
fficult to suspect early on. As described earlier, subtle early 
symptoms include personality changes, sleep disturbances, 
and visual impairment. The classic finding of myoclonic jerks 
is typically seen later in the disease course and may be the 
eventual trigger for the sCJD workup.5 
Figure 1. Repeat Electroencephalogram of the Patient
Electroencephalogram (EEG) of the patient displaying frequent triphasic spike and wave complexes. Dis-
charges were frequent and at times continuous, lasting for hours. EEG was reviewed in a double banana 
montage with sensitivity at 7 microvolts and a time base of 30 mm/s. Background activity was seen 
primarily at 4–5 Hz.
Figure 2. Brain Magnetic Resonance Imaging (MRI) of the Patient
Three fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) axial slices of the 
brain without gadolinium. Arrow: Single area of localized hyperintensity involving the right centrum se-
miovale above the lateral ventricles.
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The diagnostic criteria for CJD outlined by the World Health 
Organization and Centers for Disease Control and Prevention 
(CDC) classify CJD into either definite, probable, or possible 
based on symptomatology, EEG findings, CSF analysis, and MRI 
(Table 1). Definitive diagnosis of CJD requires a tissue biopsy 
and is confirmed post mortem. However, updated criteria which 
may be superior to the current standard have been proposed.7
Diagnostic evaluation of patients with suspected sCJD involves 
assessment of the 14-3-3 protein assay, MRI, and EEG. Studies 
have demonstrated that CSF 14-3-3 may be the most accurate 
test, with a sensitivity of 92% and a specificity of 80%.8 Typi-
cal EEG findings of sCJD show periodic sharp and slow wave 
complexes (PSWC) with a reported sensitivity and specificity 
of 66% and 74%, respectively.8 Our patient demonstrated the-
se changes; however, wave complexes consistent with NCSE 
were also present. sCJD mimicking NCSE on EEG is extremely 
rare, as only 12 prior cases of CJD masquerading as NCSE have 
been documented.6 The importance of such finding has yet 
to be determined. MRI has shown to be the superior test by 
demonstrating areas of hyperintensity in the cortical and/or 
subcortical areas with sensitivity and specificity of 92.3% and 
95%, respectively.8,9 Multiple studies found MRI to be superior 
in the evaluation of patients with suspected sCJD compared to 
EEG and 14-3-3 protein.9 With the demonstrated sensitivity and 
specificity of diffusion-weighted  imaging (DWI) and fluid-atte-
nuated inversion recovery (FLAIR) for white matter disease, MRI 
has become essential in the evaluation of rapidly progressive 
dementia.9
The National Prion Disease Pathology Surveillance Center (NP-
DPSC) provides CSF analysis for tau protein levels and the exis-
tence of 14-3-3 protein through real-time quaking-induced con-
version (RT-QuiC) for the detection of abnormal prion protein. 
The center has reported a 98.5% specificity and up to 92% sen-
sitivity in CSF analysis of 193 cases that have been autopsy-ve-
rified by the NPDPSC (Available from: http://case.edu/med/pa-
thology/centers/npdpsc/index.html; cited 2015 May 31). 
The RT-QuiC is reported as positive or negative. As reported by 
the NPDPSC, tau protein levels of 0–899 pg/mL correspond with 
a 25% probability of prion disease, 900–1,149 pg/mL with a 36% 
probability, and greater than 1,150 pg/mL with a 76% proba-
bility (Available from: http://case.edu/med/pathology/centers/
npdpsc/index.html; cited 2015 May 31). Our patient was po-
sitive for RT-QuiC and 14-3-3 protein and had a t-tau protein 
level of 6,350 pg/mL. After careful review of the literature, the 
consensus appears to be in agreement with the data reported 
by the NPDPSC. In fact, one study of 100 patients with varying 
neurodegenerative diseases found that significantly elevated 
levels of t-tau protein was found in CJD alone (CJD and variant 
CJD) (Available from: http://www.who.int/zoonoses/diseases/
Creutzfeldt.pdf; cited 2015 Jun 25).
Conclusion
Ruling out reversible encephalopathic disease is important and 
potentially life-saving, but can be challenging and time consu-
ming. CJD, particularly the sporadic subtype, is a devastating 
disease with a rapid neurological degeneration pattern. Due to 
the low incidence and varying clinical presentations, it is diffi-
cult to include CJD as a differential diagnosis without specific 
and supportive analytic measures. In the case of unknown cau-
ses of neurodegenerative decline, it is imperative that CJD be 
included in the differential, and the laboratory testing should be 
initiated early in management. There exists a short window of 
time from symptom onset to death, and diagnosis early in this 
window allows the patient to carry out his/her final wishes and 
the family time for closure. 
Unfortunately, in our patient, as well as the majority of patients 
who suffer from CJD, the diagnosis came late in the disease 
course, after significant neurological functions had deteriorated 
and the patient’s quality of life had already been significantly 
impacted. Thus, CJD needs to be quickly considered when rapid 
neurological decline or NCSE is not suggestive of another entity.
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